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Abstract
Background: 5-HT1B receptor agonists enhance cocaine intake during daily self-administration sessions but decrease cocaine 
intake when tested after prolonged abstinence. We examined if 5-HT1B receptor agonists produce similar abstinence-
dependent effects on methamphetamine intake.
Methods: Male rats were trained to self-administer methamphetamine (0.1 mg/kg, i.v.) on low (fixed ratio 5 and variable 
ratio 5) and high (progressive ratio) effort schedules of reinforcement until intake was stable. Rats were then tested for the 
effects of the selective 5-HT1B receptor agonist, CP 94,253 (5.6 or 10 mg/kg), or the less selective but clinically available 5-HT1B/1D 
receptor agonist, zolmitriptan (10 mg/kg), on methamphetamine self-administration both before and after a 21-day forced 
abstinence period during which the rats remained in their home cages.
Results: The inverted U-shaped, methamphetamine dose-response function for intake on the fixed ratio 5 schedule was shifted 
downward by CP 94,253 both before and after abstinence. The CP 94,253-induced decrease in methamphetamine intake was 
replicated in rats tested on a variable ratio 5 schedule, and the 5-HT1B receptor antagonist SB 224,289 (10 mg/kg) reversed this 
effect. CP 94,253 also attenuated methamphetamine intake on a progressive ratio schedule both pre- and postabstinence. 
Similarly, zolmitriptan attenuated methamphetamine intake on a variable ratio 5 schedule both pre- and postabstinence, and 
the latter effect was sustained after each of 2 more treatments given every 2 to 3 days prior to daily sessions.
Conclusions: Unlike the abstinence-dependent effect of 5-HT1B receptor agonists on cocaine intake reported previously, both 
CP 94,253 and zolmitriptan decreased methamphetamine intake regardless of abstinence. These findings suggest that 5-HT1B 
receptor agonists may have clinical efficacy for psychostimulant use disorders.
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Introduction
Psychostimulant addiction remains a prevalent problem 
worldwide (NDIC, 2011; NIDA, 2015), and yet there are still no 
FDA-approved, effective pharmacological treatments for psy-
chostimulant use disorders. We and others have suggested 
that the serotonin1B receptor (5-HT1BR) may be a useful target 
for medication development for these disorders (Callahan and 
Cunningham, 1995; Rocha et  al., 1997; Miszkiel et  al., 2011; 
Neisewander et  al., 2014). Advances in medicinal chemistry 
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have discovered drugs with high selectivity for 5-HT1BRs (Koe 
et al., 1992; Selkirk et al., 1998; Murray and Rees, 2009; Rodriguez 
et  al., 2014). The agonist 5-propoxy-3-(1,2,3,6-tetrahydro-4-
pyridinyl)-1H-pyrrolo[3,2-b] pyridine (CP 94,253) and the antago-
nist 1’-methyl-5-[[2’-methyl-4’-(5-methyl-1,2,4-oxadiazol-3-yl)
biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydrospiro[furo[2,3-f]
indole-3,4’-piperidine (SB 224,289) have high affinities (Ki  =  2 
and 8.2 nM, respectively) for 5-HT1BRs (Koe et al., 1992; Selkirk 
et al., 1998). The selectivity profiles of CP 94,253 and SB 224,289 
have established these drugs as useful tools for studying the 
role of 5-HT1BRs in psychostimulant addiction. Another group of 
5-HT1BR agonists are tryptamine based, including zolmitriptan 
(Zomig), which is an FDA-approved drug used to treat migraine 
headaches. Although zolmitriptan is not as selective for 5-HT1BRs 
as CP 94,253, it has a high affinity (Ki = 5.01 nM) for 5-HT1BRs.
Initial experiments examining the effects of 5-HT1BR ago-
nists found that these drugs facilitated cocaine self-administra-
tion (Parsons et al., 1998). However, we found that the effects of 
5-HT1BR agonists vary depending on whether or not animals have 
undergone abstinence. Specifically, CP 94,253 shifts the cocaine 
self-administration dose-response curve leftward when given as a 
pretreatment prior to a daily self-administration session (preabsti-
nence) but produces a downward shift when given as a pretreat-
ment prior to resumption of self-administration after prolonged 
(i.e., 21 days) abstinence (Pentkowski et al., 2009; Pentkowski et al., 
2014). In addition, CP 94,253 pretreatment increases breakpoints 
and cocaine intake on a progressive ratio (PR) schedule compared 
with vehicle pretreatment when tested during daily maintenance 
sessions. In contrast, following a 21-day period of forced absti-
nence (postabstinence), CP 94,253 decreases cocaine intake and 
response rates on the PR schedule. Furthermore, CP 94,253, atten-
uates cocaine-seeking behavior in tests of both cue-induced and 
cocaine-primed reinstatement following a few weeks of extinction 
training during which the rats were abstinent (Pentkowski et al., 
2009). Cocaine-seeking behavior under these conditions reflects 
incentive motivational effects produced by the cues and cocaine 
priming injections (Markou et al., 1993). Therefore, these results 
suggest that preabstinence administration of 5-HT1BR agonists 
facilitates the reinforcing and motivational properties of cocaine 
while postabstinence 5-HT1BR agonists attenuate these effects.
This study examined if CP 94,253 produces a similar absti-
nence-dependent decrease in methamphetamine intake. First, 
we examined CP 94,253 pretreatment effects on the metham-
phetamine self-administration dose-response function using 
low ratio schedules of reinforcement (i.e., fixed and variable 
ratio 5; FR5 and VR5). Second, we examined CP 94,253 pretreat-
ment effects on a PR schedule of methamphetamine reinforce-
ment as this more demanding schedule is particularly sensitive 
to changes in motivation for a drug. Third, we examined if the 
effects of CP 94,253 pretreatment on methamphetamine intake 
were 5-HT1BR mediated by administering the 5-HT1BR antagonist 
SB 224,289 to reverse the agonist effects. Fourth, we examined 
if CP 94,253 and SB 224,289 affected locomotor activity. Finally, 
we examined if acute and intermittent repeated treament with 
zolmitriptan affected methamphetamine intake. Since both 
methamphetamine and cocaine enhance monoaminergic neu-
rotransmission by an action at monoamine transporters, we 
hypothesized that CP 94,253 would increase methamphetamine 
intake preabstinence and decrease methamphetamine intake 
postabstinence similar to that observed with cocaine intake.
Methods
Animals
Male Sprague Dawley rats (Charles River) weighing 225 to 250 g 
were single-housed in a climate-controlled environment on a 
14:10 reverse light/dark cycle (lights off at 6:00 am). Rats had 
ad libitum access to food except for initial self-administration 
training when they were food restricted to 90% of their ad libi-
tum weights. The experiments proceeded in accordance with a 
protocol approved by the Arizona State University Institutional 
Animal Care and Use Committee.
Drugs
Methamphetamine hydrochloride (Sigma-Aldrich) was dissolved 
in bacteriostatic saline (Hospira Inc.) and filtered with 0.2-µm 
membrane Acrodisc syringe filters (PALL Corporation). CP 94,253 
hydrochloride (Tocris Bioscience) was dissolved in saline, and 
SB 224,289 hydrochloride (Tocris Biosciences) was dissolved in 
10% (2-hydroxypropyl)-β-cyclodextrin (Sigma-Aldrich) in saline 
and sonicated for 2 minutes. Zolmitriptan (Sigma-Aldrich) was 
dissolved in 10% dimethyl sulfoxide in saline and sonicated for 5 
minutes. CP 94,253, SB 224,289, and zolmitriptan were prepared 
fresh daily. Vehicle refers to the respective solvent. All drug 
injections, with the exception of self-administered metham-
phetamine, were injected at a volume of 1 mL/kg body weight.
Surgery
Rats underwent surgery for implantation of chronic indwelling 
catheters into the jugular vein as detailed previously (Pockros 
et al., 2011). Rats had 6 to 7 days of recovery before commenc-
ing self-administration training. Catheters were flushed daily 
with 0.1  mL of either timentin (experiment 1; 66.67  mg/mL; 
GlaxoSmithKline) or cefazolin (experiment 2, 3, 4, and 5; 10 mg/
mL; WG Critical Care, LLC) mixed with heparin/saline (70 U/mL; 
APP Pharmaceuticals). In addition, catheter patency was tested 
periodically by administering 0.05 mL of methohexital sodium 
(16.7 mg/mL; Jones Pharma Inc.), a dose that produces brief loss 
of muscle tone when administered i.v.
Apparatus
The operant conditioning chambers (Med Associates) contained 
an active and inactive lever, a cue light, and a tone generator as 
Significance Statement
Psychostimulant addiction (e.g., cocaine and methamphetamine) remains a prevalent problem in the United States. 
Prior studies suggest that the serotonin1B receptor (5-HT1BR) modulates cocaine reinforcement and incentive motivation 
dependent on whether there is a period of abstinence from cocaine in male rats. This study demonstrates that measures 
of methamphetamine drug taking in rats are attenuated by pretreatment with 5-HT1BR agonists, including the FDA-
approved agonist zolmitriptan, regardless of abstinence history. Our findings suggest that 5-HT1BR agonists may be useful 
for treating psychostimulant use disorders.
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previously described (Pentkowski et al., 2010). All chambers had 
infusion pumps (Med Associates) that connected to liquid swiv-
els (Instech) fastened to an outlet polyethylene tubing sheltered 
within a metal leash (PlasticsOne) that attached to the rat’s cathe-
ter. All operant conditioning chambers were housed within sound 
attenuating boxes that contained a ventilation fan.
General Procedures
Experimental sessions commenced at approximately the same 
time of day, 6 days/week during the rats’ dark cycle. Rats were 
first trained to self-administer 0.1  mg/kg (i.v.) methampheta-
mine on an FR1 schedule of reinforcement, and they later pro-
gressed to either a FR5, VR5, or PR schedule based on individual 
performance. In all experiments, schedule advancement during 
training occurred once rats received at least 10 reinforcers/ses-
sion for 2 consecutive sessions, and testing commenced once 
rats reached a stability criterion of <15% variability in the num-
ber of infusions obtained across 3 consecutive sessions. The 
training dose was choosen as it has been shown to be effective 
in producing methamphetamine acquisition (Kitamura et  al., 
2006; Clemens et al., 2006; Krasnova et al., 2010). The VR5 sched-
ule was chosen for its tendency to sustain consistent steady 
response rates (Domjan, 2003). Session length was 2 hours, 
except for training and testing on the PR schedule for which ses-
sions were 4 hours long to capture break points in most rats. In 
the PR schedule, the number of active lever responses required 
to obtain each subsequent infusion increased exponentially 
(e.g., 1, 2, 4, 6, 9, 12, 15, etc.), identical to the exponential equa-
tion from Richardson and Roberts (1996). The PR schedule was 
chosen because it is progressively more effortful to obtain rein-
forcement, reflecting in part how motivated a rat is to work for 
methamphetamine (Markou et al., 1993). Therefore, the pattern 
of changes across various schedules of reinforcement can help 
inform how treatments affect behavioral processes. Completion 
of any of the operant schedules activated the tone and light 
cue followed 1 second later by an infusion of 0.1 mL metham-
phetamine delivered across 6 seconds (dose is given in the spe-
cific experiments section). The tone, light, and pump were then 
turned off, and simultaneously a house-light was activated for 
20 seconds to signal a timeout period during which additional 
lever responses were recorded but had no programmed conse-
quences. After the timeout period, the house-light turned off 
and methamphetamine was available again. Abstinence from 
methamphetamine occurred for 21 or more consecutive days, 
during which the rats were maintained in the home cage, han-
dled, and weighed daily for i.v. administration of timentin or 
cefazolin to maintain catheter patency.
Experiment 1: Effects of CP 94,253 on the 
Methamphetamine Self-Administration Dose-
Response Function Pre- and Postabstinence
The timeline for this experiment is outlined in Figure 1. 
Beginning 2 days prior to the start of training and continuing 
throughout the experiment, rats were food restricted to 90% of 
their initial free-feeding body weight (291 ± 4.6 g). During train-
ing, rats progressed from a FR1 to FR5 schedule (~17–20 sessions) 
after reaching a criterion of ≥10 infusions for 2 consecutive ses-
sions. Once reinforcement rates met the stability criterion on 
the FR5, the rats commenced training on a within-session dose-
response procedure. For these sessions, each methamphetamine 
dose (0.003, 0.01, 0.03, 0.1, and 0.30 mg/kg, i.v.) was available in 
ascending order for 30 minutes with a 5-minute time-out period 
between doses. After again meeting the stability criterion for 
reinforcement rates across the within-session dose-response 
training days (20–28 sessions), rats were randomly assigned to 
receive an injection of either CP 94,253 (5.6 mg/kg, s.c.) or vehi-
cle 15 minutes prior to their daily dose-response session. The 
dose of CP 94,253 was selected based on our previous research 
demonstrating that it selectively reduces cocaine intake without 
affecting sucrose intake (Pentkowski et al., 2009). After this first 
test session, additional training sessions were given until rats 
met the stability criterion. Then rats were tested again, receiv-
ing the treatment opposite from their first treatment (i.e., ani-
mals that received vehicle first, now received CP 94,253 and vice 
versa). After this test session, rats underwent abstinence for 21 
days, during which they remained in their home cages but con-
tinued to receive daily i.v. administration of heparin/antibiotic 
to maintain catheter patency.
For the postabstinence tests, rats received CP 94,253 or vehi-
cle, and 15 minutes later, they were given access to methamphet-
amine using the same within session dose-response procedure 
as used during preabstinence tests. Rats then remained absti-
nent in the home cage for 3 days to allow time for CP 94,253 to 
be eliminated and to reinstate an abstinence period prior to the 
second test. On the second test day, the rats received the treat-
ment opposite from that given prior to the first postabstinence 
test. A  total of 10 rats ran through the entire experiment and 
their average final weight was 468 ± 4.94 g.
Experiment 2: Effects of CP 94,253 on 
Methamphetamine Self-Administration on a 
Progressive Ratio Schedule Pre- and Postabstinence
The timeline for this experiment is outlined in Figure 2. A new 
cohort of experimentally naïve rats was food restricted and 
trained to self-administer methamphetamine, progressing from 
a FR1 to a VR5 schedule during 2-hour sessions (11–13 sessions) 
using the same procedure as the previous experiment, with the 
exception that food restriction was gradually discontinued once 
rats were on the VR5 schedule. After meeting the stability crite-
rion on the VR5 schedule, rats were trained on the PR schedule 
of methamphetamine reinforcement during 4-hour sessions 
until again meeting the stability criterion (10–18 sessions). We 
capped session length to 4 hours to ensure that CP 94,253 would 
remain effective throughout the test (Parsons et al., 1998). We 
also reduced the methamphetamine dose to one-half the train-
ing dose (0.05 mg/kg, i.v.) with the intention that more rats 
would reach break point during the 4-hour session. Breakpoint 
was defined as the last schedule of reinforcement completed 
prior to a 1-hour period during which the next required ratio 
failed to be completed, or 4 hours had elapsed, whichever came 
first. After rats met the stability criterion on the PR schedule, 
they were randomly assigned to either a CP 94,253 (10 mg/kg, 
s.c.; n = 8) or a vehicle group (n = 7), counterbalanced for similar 
number of total drug infusions during training. The dose of CP 
94,253 was higher than the previous experiment to sustain CP 
94,253 levels throughout testing, and based on previous research 
this dose selectively decreases cocaine intake while not affect-
ing sucrose intake (Pentkowski et al., 2009). These groups 
received their respective treatments 15 minutes before test-
ing on the PR schedule. After testing, both groups of rats were 
placed into abstinence for 21 days as described in experiment 
1. Postabstinence, both groups received their injections, which 
were identical to those given preabstinence, 15 minutes prior to 
a test for resumption of methamphetamine self-administration 
on the PR schedule.
Downloaded from https://academic.oup.com/ijnp/article-abstract/20/8/644/3748289/Preclinical-Evidence-That-5-HT1B-Receptor-Agonists
by Arizona State University West user
on 07 September 2017
Garcia et al. | 647
Experiment 3: Reversing the Attenuating 
Effects of CP 94,253 on Methamphetamine Self-
Administration with SB 224,289
The timeline for this experiment is outlined in Figure 3. A new 
cohort of experimentally naïve rats was trained to self-admin-
ister methamphetamine, progressing from a FR1 to a VR5 
schedule (~12–17 sessions) of methamphetamine (0.1 mg/kg, i.v.) 
reinforcement. Rats were food restricted only during acquisition 
of self-administration and all sessions lasted for 2 hours. Once 
reinforcement rates stabilized under free feeding conditions 
(~4–12 sessions), rats were randomly assigned to 1 of 2 groups 
(n = 14 and 17, respectively); Group 1 received an i.p. injection 
of either vehicle or SB 224,289 (10 mg/kg, i.p.) 30 minutes prior 
Figure 1. Effects of the 5-HT1B receptor agonist, CP 94,253 on infusions (A,D), active lever (B,E), and inactive lever (C,F) responses on a FR5 schedule of methamphetamine 
(0.1 mg/kg, i.v.) reinforcement during pre- and postabstinence tests (left and right panels, respectively). Data are expressed as the mean (± SEM) during the 30-minute 
test period for each of the methamphetamine doses tested (0.003–0.30 mg/kg, i.v.). Rats (n = 10) were tested twice, receiving pretreatment with vehicle (1 mL/kg, s.c.; 
open squares) prior to one test and CP 94,253 (5.6 mg/kg, s.c.; filled triangles) prior to the other test, with order of pretreatment counterbalanced. Insets in A-E show 
a main effect of CP 94,253 averaged across methamphetamine doses. Asterisks (*) represent a difference from vehicle condition (main effect or Tukey’s posthoc test, 
P < .05).
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to the first test and the opposite treatment injection 30 min-
utes prior to the second test (i.e., rats that received vehicle on 
test 1 received SB 224,289 on test 2 and vice versa). Group 1 also 
received a vehicle injection 15 minutes prior to both tests. For 
Group  2, identical procedures were followed except that rats 
received vehicle followed by CP 94,253 (5.6 mg/kg, s.c.) on one 
test day and SB 224,289 (10  mg/kg, i.p.) followed by CP 94,253 
(5.6 mg/kg, s.c.) on the other test day.
In addition to testing whether the antagonist would reverse 
the effects of the agonist in this experiment, we also verified 
that these rats showed a CP 94,253-induced decrease in meth-
amphetamine intake postabstinence (not included on time-
line). A subset of rats, randomly selected from both Group 1 and 
Group 2, underwent 21 days of abstinence as described above. 
They were then assigned to 2 groups, counterbalanced for the 
number of infusions obtained during training. One group (n = 11) 
received an injection of CP 94,253 (5.6 mg/kg, s.c.) while the other 
group (n = 11) received an injection of vehicle 15 minutes prior to 
a test for resumption of methamphetamine self-administration 
(0.1 mg/kg, i.v.).
Experiment 4: Effects of 5-HT1BR Drugs on 
Spontaneous Locomotion
The timeline for this experiment is outlined in Figure  4. Rats 
from experiment 2 were used and they had a history of metham-
phetamine self-administration (38 sessions) and had undergone 
an abstinence period (23 days). On abstinence day 24, rats were 
placed into locomotor test chambers for a 60-minute habitua-
tion period. The test chambers (45.72 x 25.4 x 20.32  cm) were 
similar to the home cages and had a camera mounted above 
to record horizontal movement with Topscan software (Clever 
Systems). The rats were then tested twice for locomotor activity 
with 3 rest days intervening the 2 test days. They remained in 
their home cages during rest days. Thirty minutes prior to the 
first test, rats were pretreated with either vehicle or SB 224,289 
(10 mg/kg, i.p.) and 30 minutes prior to the second test the rats 
received the opposite treatment as that given on the first test 
(i.e., rats that received vehicle on test 1 received SB 224,289 on 
test 2 and vice versa). They were also randomly assigned to 1 of 
2 groups. Group 1 (n = 7) received a vehicle injection 15 minutes 
prior to both tests, and Group 2 (n = 7) received CP 94,253 (10 mg/
kg, s.c.) 15 minutes prior to both tests. The tests began by placing 
the rat into the test chamber, and distance traveled was meas-
ured for 2 hours.
Experiment 5: Effects of Zolmitriptan on 
Methamphetamine Self-Administration Pre- and 
Postabstinence
The timeline for this experiment is outlined in Figure  5. Rats 
that were used in experiment 3 were tested for the effects of zol-
mitriptan on methamphetamine after achieving stable SA rates 
on a VR5 schedule (~3–11 sessions) of methamphetamine rein-
forcement (0.1 mg/kg, i.v.) across 2-hour training sessions. Rats 
were then randomly assigned to either a zolmitriptan (10 mg/
kg, s.c.; n = 9) or a vehicle treatment group (n = 6), counterbal-
anced for similar number of total drug infusions. Rats received 
their assigned treatment 15 minutes prior to the start of a self-
administration session. Then rats underwent a period of absti-
nence for 29 to 36 days followed by a test phase. During the test 
phase, the rats again received their assigned treatment of either 
Figure 2. Effects of the 5-HT1B receptor agonist, CP 94,253, on infusions (A), breakpoints (B), active lever (C), and inactive lever (D) responses under a progressive ratio 
schedule of methamphetamine (0.05 mg/kg, i.v.) reinforcement during pre- and postabstinence tests. Data are expressed as the mean (± SEM) during 4-hour sessions. 
Rats were pretreated 15 minutes prior to the start of the test sessions with either vehicle (1 mL/kg, s.c.; white bars; n = 7) or CP 94,253 (10 mg/kg, s.c.; black bars; n = 8). 
Asterisks (*) represent a difference from vehicle at each time point (Tukey’s posthoc test, P < .05).
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zolmitriptan or vehicle 15 minutes prior to each of 3 self-admin-
istration sessions with 2 to 3 self-administration sessions with-
out treatment between each of the treatment test days.
Data Analysis
Statistical analyses were conducted with IBM SPSS Statistics 
v.  23. Descriptive statistics are reported as the mean ± SEM. 
Self-administration data, including active and inactive lever 
responses, and infusions obtained were analyzed by either 
repeated-measures or a mixed-design ANOVA with drug 
pretreatment(s) and dose of methamphetamine as between-
subject or within-subject factors depending on the experimen-
tal design. In addition, breakpoint and total distance travelled 
were analyzed as described above for experiments 2 and 4, 
respectively. All sources of significant effects were further ana-
lyzed by Tukey’s posthoc tests. There was some attrition in each 
experiment due to catheter failure or failure to acquire SA.
Results
Experiment 1
Methamphetamine produced an inverted U-shaped dose-effect 
function, and CP 94,253 decreased methamphetamine infusions 
and active lever responses both pre- and postabstinence (Figure 1). 
For the preabstinence tests, there were main effects of metham-
phetamine dose for both infusions [F (4, 36) = 17.67, P < .05] and 
active lever responses [F (4, 36) = 8.40, P < .05]. Posthoc tests indi-
cated that the 0.01- and 0.03-mg/kg doses produced higher values 
than the lowest dose (0.003 mg/kg) and the highest dose (0.30 mg/
kg) produced lower values than all doses except 0.10 mg/kg (Tukey’s 
comparisons, P < .05) (Figure 1A,B). There were also main effects of 
treatment, which indicated that averaged across methampheta-
mine dose, rats exhibited lower infusion and active lever response 
rates when pretreated with CP 94,253 than when pretreated with 
vehicle (Figure  1A,B,insets). There were no significant effects for 
inactive lever responses during preabstinence tests (Figure 1C).
Analysis of postabstinence infusions showed main effects of 
treatment [F (1, 9) = 30.74, P < .05] and methamphetamine dose 
[F (4, 36)  =  35.27, P < .05], as well as a treatment by metham-
phetamine dose interaction [F (4, 36) = 2.87, P < .05]. CP 94,253 
pretreatment decreased infusions at the 3 lowest doses of meth-
amphetamine compared with vehicle pretreatment (Tukey’s 
comparisons, P < .05) (Figure 1D). The analysis of postabstinence 
active lever responses also revealed main effects for treat-
ment [F (1, 9) = 10.38, P < .05] and methamphetamine dose [F (4, 
36) = 22.20, P < .05], but no treatment by methamphetamine dose 
interaction. The main effect of methamphetamine dose was due 
to the inverted U-shaped dose-response function similar to pre-
abstinence. The main effect of treatment shows that averaged 
across methamphetamine doses, rats exhibited lower infusions 
and active lever response rates when pretreated with CP 94,253 
than when pretreated with vehicle (Figure 1D,E, insets). There 
Figure 4. Effects of 5-HT1B receptor drugs on spontaneous locomotion. Rats were 
placed on abstinence from methamphetamine for a total of 29 days following 
acquisition and stabilization on a progressive ratio schedule of reinforcement. 
Habituation to the locomotor testing chambers occurred on abstinence day 24. 
On the first test day, rats (group 1: n = 7, group 2: n = 7) received a pretreatment 
of either vehicle (Veh, white bar) or SB 224,289 (SB; 10 mg/kg, i.p., gray bar) 30 
minutes before commencement of the session. They then received a treatment 
of either vehicle (Veh) or CP 94,253 (CP; 10 mg/kg, s.c., black bar) 15 minutes prior 
to the same session. Conditions were identical on the second test day for all rats 
except that the pretreatment given 30 minutes before session start was reversed 
such that rats who had received vehicle previously were given SB 224,289 and 
vice versa. All rats underwent 3 days off between tests 1 and 2 while remain-
ing in abstinence. Data are expressed as the mean (+SEM) distance traveled in 
meters across the 2-hour session. Pretreatment with 5-HT1B receptor drugs pro-
duced no significant differences in spontaneous locomotion.
Figure 3. Reversing the attenuating effects of CP 94,253 on methamphetamine 
(0.1 mg/kg, i.v.) self-administration with SB 224,289 during tests that occurred 
preabstinence. On the first test day, rats (group 1: n = 14, group 2: n = 17) received 
a pretreatment of either vehicle (Veh, white bar) or SB 224,289 (SB; 10 mg/kg, i.p., 
gray bar) 30 minutes before the 2-hour session. They then received a treatment 
of either vehicle (Veh) or CP 94,253 (CP; 5.6 mg/kg, s.c.; black bar) 15 minutes 
prior to the test session that commenced under a VR5 schedule of reinforce-
ment. Conditions were identical on the second test day for all rats except that 
the pretreatment given 30 minutes before session start was reversed such that 
rats that had received vehicle previously were given SB 224,289 and rats that 
had received SB 224,289 previously were given vehicle. Data are expressed as the 
mean (+ SEM). Asterisk (*) represents a difference from all other groups (Tukey’s 
posthoc test, P <.05).
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were no significant effects for inactive lever responses during 
the postabstinence tests (Figure 1F).
Experiment 2
CP 94,253 decreased methamphetamine infusions, breakpoint, 
and active lever responses (Figure  2, A-C). Most rats reached 
breakpoint within the 4-hour test during both the preabstinence 
(80%) and postabstinence (73%) tests. The analyses showed main 
effects of pretreatment across pre- and postabstinence tests for 
infusions [F (1, 13) = 9.86, P < .05], breakpoints [F (1, 13) = 6.46, 
P < .05], and active lever responses [F (1, 12)  =  11.09, P < .05]. 
In each case, CP 94,253 pretreatment decreased these measures 
compared with the vehicle pretreatment (Tukey’s comparisons, 
P < .05). There were no main effects for inactive lever responses 
(Figure 2D) and no pretreatment by time interaction effects for 
any of the measures.
Experiment 3
CP 94,253 decreased methamphetamine infusions, and this 
effect was blocked by SB 224,289 (Figure 3). Data analysis showed 
a main effect of the first pretreatment (i.e., vehicle vs SB 224,289) 
[F (1, 29) = 6.86, P < .05] and an interaction between the first and 
second (vehicle vs CP 94,253) pretreatments [F (1, 29) = 12.52, P < 
.05]. Posthoc tests showed that pretreatment with vehicle + CP 
94,253 decreased methamphetamine infusions compared with 
all other pretreatment conditions, including SB 224,289  + CP 
94,253 (Tukey’s comparisons, P < .05). This finding indicates that 
administration of the antagonist SB 224,289 blocked the attenu-
ating effect of CP 94,253 on methamphetamine intake, suggest-
ing this effect was mediated by 5-HT1BRs. There were no effects 
for active or inactive lever responses (data not shown).
The rats in this experiment underwent 21 days of abstinence 
and were then tested for the effects of CP 94,253 (5.6  mg/kg, 
s.c.) on resumption of methamphetamine self-administration 
(0.1 mg/kg, i.v.). Similar to the results from experiment 1, pre-
treatment with a 5.6-mg/kg dose of CP 94,253 decreased the 
number of infusions and active lever responses compared with 
pretreatment with vehicle during the postabstinence tests (data 
not shown). The mean number of methamphetamine infusions 
obtained in the vehicle vs CP 94,253 pretreatment groups was 
12.40  ±  0.88 and 8.90  ±  0.71, respectively [t (9)  =  7.72, P < .05]. 
The mean number of active lever responses in the vehicle vs CP 
94,253 pretreatment groups was 70.30 ± 20.81 and 49.20 ± 17.89, 
respectively [t (9) = 2.62, P < .05]. There was no group difference 
for inactive lever responses.
Experiment 4
Neither CP 94,253 or SB 224,289 pretreatment altered locomo-
tor activity (Figure 4). There were no main or interaction effects 
between treatment and the total distance traveled by rats.
Experiment 5
Acute zolmitriptan treatment decreased methamphetamine 
infusions and active lever responses during preabstinence tests 
(Figure  5A,B). Comparisons between vehicle and zolmitriptan 
showed a difference in infusions [t (10) = 3.50, P < .05] and active 
lever responses [t (10) = 2.90, P < .05]. There were no effects on 
inactive lever responses after vehicle or zolmitriptan treatment 
with means of 39.18 ± 16.37 and 16.55 ± 6.41, respectively.
Zolmitriptan pretreatment given intermittently across 3 
postabstinence tests consistently decreased infusions and 
active lever responses (Figure 5C,D). The ANOVA showed a main 
effect of treatment group for infusions [F (1, 11) = 21.92, P < .05] 
but no effect of treatment day or treatment group by treatment 
day interaction. For active lever responses, there were signifi-
cant main effects of treatment group [F (1, 10) = 21.17, P < .05] 
and treatment day [F (2, 20)  =  6.08, P < .05], but no treatment 
group by treatment day interaction. Posthoc tests for treatment 
day showed that zolmitriptan treatment produced lower active 
lever response rates on day 2 compared with treatment days 1 
and 3. There were no effects on inactive lever responses after 
vehicle or zolmitriptan treatment with means of 7.89 ± 3.68 and 
3.56 ± 0.68, respectively.
Discussion
Unlike the abstinence-dependent modulatory role of 5-HT1BR 
agonists on cocaine intake that we observed previously 
(Pentkowski et al., 2012, 2014), this study found that 5-HT1BR ago-
nists attenuated methamphetamine intake when given either 
pre- or postabstinence. Specifically, a moderate dose of CP 94,253 
(5.6 mg/kg, s.c.) decreased methamphetamine intake and active 
lever response averaged across methamphetamine dose avail-
able both when administered during maintenance of daily self-
administration sessions and following a period of abstinence 
(main effect of pretreatment, Figure 1, insets). After abstinence, 
the effect of CP 94,253 was more pronounced at lower doses of 
methamphetamine, primarily because intake appeared higher 
under the vehicle pretreatment condition postabstinence com-
pared with preabstinence. This enhancement of cocaine intake 
postabstinence is consistent with sensitized cocaine self-admin-
istration reported previously (Schenk and Partridge, 1997). Thus, 
the findings suggest that CP 94,253 attenuates expression of the 
Figure  5. Effects of zolmitriptan, a 5-HT1B/1D receptor agonist, on infusions 
(A,C), and active lever (B,C) responses on a VR5 schedule of methamphetamine 
(0.1  mg/kg, i.v.) reinforcement during pre- and postabstinence tests (left and 
right panels, respectively). Data are expressed as the mean (±SEM). Rats were 
pretreated 15 minutes prior to the start of the 2-hour sessions with either vehi-
cle (white bar/open circles; n = 6) or zolmitriptan (10 mg/kg, s.c.; black bar/filled 
squares; n = 9). Asterisks (*) represent a difference from vehicle condition (t test 
or ANOVA main effect, P < .05).
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abstinence-induced, enhanced sensitivity to methampheta-
mine observed with vehicle pretreatment. CP 94,253 (10  mg/
kg, s.c.) also decreased methamphetamine intake (0.05 mg/kg, 
i.v.) under a PR schedule of reinforcement both pre- and postab-
stinence (Figure 2), further suggesting attenuation of metham-
phetamine reinforcing and/or motivational effects. Importantly, 
administration of the 5-HT1BR antagonist, SB 224,289 (10  mg/
kg, i.p.), blocked the attenuating effects of CP 94,253 (5.6 mg/kg, 
s.c.) on methamphetamine intake in rats tested during mainte-
nance of self-administration on a VR5 schedule (Figure 3), sug-
gesting that the effects of the agonist are mediated by 5-HT1BRs. 
Finally, we report that zolmitriptan (10 mg/kg, s.c.) also attenu-
ated methamphetamine intake on a VR5 schedule. Zolmitriptan 
treatment given acutely during maintenance, as well as given 
intermittently following abstinence, decreased methampheta-
mine intake and active lever responses (Figure 5).
There are a number of possible reasons for the 5-HT1BR ago-
nist-induced decreases in methamphetamine self-administra-
tion, including an effect on methamphetamine reinforcement 
value and/or incentive motivation, an effect on anxiety, or an 
effect on motor capability. The decrease in methamphetamine 
intake is unlikely due to impairments in motor capability, as 
treatment with the 5-HT1BR ligands did not alter spontaneous 
locomotion (Figure 4) or inactive lever responses at the doses 
used in the present study. Furthermore, previous research from 
our laboratory has shown that CP 94,253 (0.3–10.0 mg/kg, s.c.) 
has no effect on sucrose reinforcement (Pentkowski et al., 2009). 
Although the antagonist SB 224,289 decreases cocaine-induced 
locomotion in drug naïve rats (Hoplight et al., 2005), it has no 
effect on locomotion in rats with a history of cocaine self-
administration (Pentkowski et al., 2009, 2014). Thus, it seems 
unlikely that CP 94,253 or SB 224,289 altered methamphetamine 
intake by impairing motor capability.
We cannot rule out the possibility that CP 94,253 may 
have influenced methamphetamine intake nonspecifically by 
increasing anxiety-like behaviors rather than attenuating rein-
forcement per se. Indeed, previous studies have found that 
either 5-HT1BR agonists or antagonists can increase baseline and 
cocaine-induced anxiety-like behaviors (Lin and Parsons, 2002; 
Hoplight et al., 2005; Pentkowski et al., 2009). It is important to 
note that the rats in these previous studies were naïve to the 
experimental procedures used to assess anxiety-like behaviors, 
which would likely maximize any potential drug effect. In con-
trast, rats tested for CP 94,253 effects on methamphetamine 
self-administration in the present study were well habituated to 
the testing environment, which would likely minimize potential 
anxiogenic effects. Furthermore, animals with increased expo-
sure to stress, such as foot-shock, often increase rather than 
decrease drug intake (Goeders and Guerin, 1994; Ahmed and 
Koob, 1997; Piazza and Le Moal, 1998; Logrip et al., 2012), mitigat-
ing the idea that CP 94,253 may have induced anxiety-like states 
that interfered with responding. Finally, it seems that potential 
anxiogenic effects of CP 94,253 on reinforcement would mani-
fest as a decrease in both sucrose and psychostimulant intake, 
yet CP 94,253 has been shown to selectively decrease cocaine 
intake (Pentkowski et al., 2009).
 We suggest that the most likely explanation for the agonist-
induced decreases in methamphetamine intake in the present 
study is that 5-HT1BRs modulate psychostimulant reinforce-
ment and/or incentive motivation (Pentkowski et al., 2012, 
2014). The decrease of methamphetamine intake in response 
to 5-HT1BR stimulation following abstinence may result from 
an attenuation of the expression of enhanced sensitivity to the 
reinforcing effects of methamphetamine. This explanation is 
consistent with our previous findings that 5-HT1BR agonists or 
5-HT1BR overexpression by viral gene transfer attenuate cocaine 
self-administration following a period of abstinence, as well 
as reduce cocaine-seeking behavior (Pentkowski et al., 2009, 
2012, 2014). Furthermore, these agonist effects are reversed by 
5-HT1BR antagonists, including SB 224,289, supporting a 5-HT1BR 
mechanism.
We were surprised that CP 94,253 attenuated metham-
phetamine intake prior to any abstinence given that this 
same treatment enhances cocaine intake prior to abstinence 
(Pentkowski et al., 2009, 2014). However, others have shown 
that 5-HT1BR agonists attenuate d-amphetamine intake with-
out prolonged abstinence, as well as attenuate d-ampheta-
mine-induced responding for conditioned reward (Fletcher 
and Korth, 1999; Fletcher et al., 2002; Miszkiel et al., 2012; 
Miszkiel and Przegalinski, 2013). Therefore, the 5-HT1BR ago-
nist enhancement of cocaine intake prior to abstinence may 
be due to differences in the pharmacological actions of cocaine 
vs amphetamines. While both amphetamines and cocaine 
inhibit and downregulate 5-HT, dopamine, and norepineph-
rine transporters (Azzaro and Rutledge, 1973; Ritz, Cone, and 
Kuhar, 1990), they interact differently with the transporters. 
Amphetamines, including methamphetamine, not only inhibit 
monoamine transport, but also redistribute intracellular mon-
oamines by acting at the vesicular monoamine transporter 
causing release of monoamines into the cytosol while at the 
same time reversing monoamine transport across the plasma 
membrane, resulting in monoamine release (Sulzer et al., 
1995; Sager and Torres, 2011; Panenka et al., 2013). Cocaine and 
amphetamines also interact at different sites on the dopamine 
transporter and produce differential effects on the releas-
able vesicular pool and on regulation of vesicular monoamine 
transporter (Thomsen et al., 2009). The latter effects may result 
in differences in the releasable pool of dopamine after cocaine 
vs methamphetamine following acute or subchronic adminis-
tration (Brown et al., 2001).
Although the specific mechanisms responsible for the atten-
uating effect of 5-HT1BR agonists on cocaine and methampheta-
mine self-administration are unclear, we hypothesize that such 
mechanisms may involve a dysregulation of 5-HT1BR functions 
(Neisewander et al., 2014). 5-HT1BRs are widely distributed in 
the brain (Bruinvels et al., 1994; Lanfumey and Hamon, 2004; 
Varnas et al., 2005; Clark et al., 2006) and are expressed as either 
5-HT terminal autoreceptors or heteroreceptors on terminals of 
non-5-HTergic cells. In both cases, these receptors negatively 
couple to adenylyl cyclase activity via G-proteins and func-
tion to inhibit neurotransmitter release (Hen 1992; Sari, 2004; 
McDevitt and Neumaier, 2011; Barnes and Neumaier, 2011). 
Several manipulations in the mesolimbic system have provided 
evidence for a modulatory role of 5-HT1BRs in psychostimulant 
addiction; specifically, overexpression of 5-HT1BRs in the nucleus 
accumbens of rats facilitates the rewarding and reinforcing 
effects of cocaine (Neumaier et al., 2002; Pentkowski et al., 2012). 
Furthermore, local activation of 5-HT1BRs in the ventral tegmen-
tal area alters cocaine-induced increases in dopamine levels 
in the nucleus accumbens and cocaine-induced decreases in 
gamma-aminobutyric acid levels (Parsons et al., 1999; O’Dell and 
Parsons, 2004). Similarily, activation of 5-HT1BRs in the nucleus 
accumbens dose-dependently decreases the rewarding and 
reinforcing effects of amphetamine (Fletcher and Korth, 1999; 
Fletcher, 2002).
The present findings suggest that 5-HT1BRs are potential 
targets for developing pharmacotherapies for psychostimu-
lant addiction. Here we show that the clinically available 
anti-migraine medication zolmitriptan, which is a 5-HT1B/1DR 
agonist, attenuated methamphetamine intake. The attenuation 
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of methamphetamine intake was likely mediated, at least in 
part, by stimulation of 5-HT1BRs, although it is possible that 
5-HT1DRs may have also contributed to the attenuation effect. 
Zolmitriptan, unlike CP 94,253, has a higher affinity for 5-HT1DRs 
(Ki  =  0.63  nM) than for 5-HT1BRs (Ki  =  5.01  nM; Murray, et  al., 
2011). CP 94,253 also has affinity for 5-HT1DRs (Ki = 49 nM; Koe 
et al., 1992), and therefore 5-HT1DRs may also contribute to its 
effects on methamphetamine self-administration. The effects 
of zolmitriptan on methamphetamine self-administration were 
not likely due to a decrease in general activity, as we did not 
observe any differences in inactive lever responses in our treat-
ment groups. Furthermore, previous research found that zolmi-
triptan (1–30 mg/kg, i.p.) attenuates alcohol-induced aggression 
in mice but has no effect on locomotion (de Almeida et al., 2001).
In conclusion, this study provides evidence that the selective 
5-HT1BR agonist, CP 94,253, attenuates methamphetamine self-
administration pre- and postabstinence under several schedules 
of reinforcement and in an antagonist-reversible manner. These 
findings build upon previous research demonstrating similar 
effects of 5-HT1BR agonists on d-amphetamine self-adminis-
tration (Fletcher and Korth, 1999; Fletcher et al., 2002; Miszkiel 
et  al., 2012; Miszkiel and Przegalinski, 2013), and together the 
effect of the agonists on self-administration of amphetamines 
contrasts with the enhanced cocaine self-administration that 
has been observed prior to any abstinence (Pentkowski et  al., 
2009, 2014). These results suggest that 5-HT1BR agonists may 
differentially modulate cocaine and methamphetamine self-
administration initially, but that after a period of abstinence, 
the agonists inhibit the reinforcing effects of both psychostim-
ulants. The latter findings suggest that 5-HT1BR agonists may 
have potential therapeutic effects for psychostimulant abuse. 
In addition, we have provided evidence that the FDA-approved 
5-HT1D/1BR agonist, zolmitriptan, also attenuates methampheta-
mine self-administration both pre- and postabstinence. Our 
findings suggest that 5-HT1BR agonists warrant further investi-
gation as putative treatments of psychostimulant use disorders. 
Important future directions include determining the neural 
circuitry involved in the agonist effects, whether the effects 
are also observed in female rats, and whether the effects are 
observed in rats given more extensive access to the stimulants 
and more extensive abstinence.
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